ACTU

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with challenging diseases in high unmet medical need areas. Headquartered in Fort Worth, Texas, the company advances a pipeline of product candidates targeting rare diseases and oncology indications. Actuate's lead program, elraglusib (formerly known as 9-ING-41), is a small molecule glycogen synthase kinase-3 beta (GSK-3β) inhibitor being evaluated in multiple clinical trials for various solid tumors and hematologic malignancies. The company operates as a development-stage enterprise, directing resources toward advancing its clinical programs through investigator-sponsored trials and company-sponsored studies. Actuate maintains strategic collaborations with academic medical centers and research institutions to support its clinical development efforts. The company pursues a capital-efficient business model by leveraging partnerships and focusing on specific patient populations where GSK-3β inhibition may provide meaningful clinical benefit. In recent periods, Actuate has concentrated on advancing elraglusib through Phase 1/2 trials in pancreatic cancer, acute myeloid leukemia, and other malignancies, while also exploring potential combination therapy approaches. As a small-cap biopharmaceutical company, Actuate operates with a lean organizational structure typical of early-stage drug developers, relying on contract research organizations and external collaborators to execute its clinical programs.